secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001193125-26-107152
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX reports 2025 revenue $76.2M, down 45% YoY; cash $137.1M; Astellas collaboration ends
--------------------------------------------------------------------------------

- Revenue $76.2M (down from $138.1M in 2024) on completion of BMS collaboration and lower collaboration milestones.
- Cash and investments $137.1M at Dec 31, 2025, up from $100.6M; cash runway to Q2 2027.
- Astellas terminated preclinical alliance effective Q2 2026; research with BMS, Amgen, Regeneron, Moderna continues.
- Varseta-M Phase 1 data positive; FDA alignment for potential registrational trial in late-line CRC targeted mid-2026.
- CX-801 Phase 1 combo with KEYTRUDA in melanoma initial proof-of-concept data expected by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526107152/0001193125-26-107152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526107152/ctmx-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-107152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer